Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Bebtelovimab  COVID-19 treatment studies for Bebtelovimab  C19 studies: Bebtelovimab  Bebtelovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
 
    
  
Bebtelovimab for COVID-19
5 studies from 48 scientists
12,949 patients in 1 country
One study shows statistically significant improvement in isolation.
Efficacy is variant dependent.
COVID-19 Bebtelovimab studies. Jun 2023. c19early.org/bt
0 0.5 1 1.5+ All studies 42% Mortality 60% Hospitalization 35% Viral clearance 36% RCTs -151% Early 42% Favorsbebtelovimab Favorscontrol
Bebtelovimab COVID-19 studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary]. Recent:
Sridhara
Molina
Kip.
Bebtelovimab has been officially adopted in 1 country. Submit updates/corrections.
Apr 28
Sridhara et al., PLOS ONE, doi:10.1371/journal.pone.0279326 Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
86% lower mortality [p=0.25], 25% lower combined mortality/hospitalization [p=0.31], and 11% lower hospitalization [p=0.78]. PSM retrospective 19,778 high-risk outpatients in the USA, showing no significant difference in outcomes with bebtelovimab treatment.
Apr 16
Molina et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396 Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5
57% lower mortality [p=0.14], 59% lower ICU admission [p=0.05], 56% lower hospitalization [p<0.0001], and 33% higher progression [p=0.001]. Retrospective 3,739 patients treated with bebteloviman in the USA and matched controls, showing lower mortality and hospitalization with treatment, but higher emergency department visits.
Apr 4
Kip et al., Annals of Internal Medicine, doi:10.7326/M22-1286 Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
20% lower combined mortality/hospitalization [p=0.65]. Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with s..
Nov 17
Planas et al., bioRxiv, doi:10.1101/2022.11.17.516888 (Preprint) (In Vitro) Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
In Vitro study suggesting a lack of efficacy for bebtelovimab with BQ.1.1.
Oct 27
Dryden-Peterson et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac565 Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system
86% lower mortality [p=0.25], 43% lower combined mortality/hospitalization [p=0.14], and 29% lower hospitalization [p=0.53]. Retrospective 377 outpatients in the USA and matched controls, showing lower hospitalization/mortality with bebtelovimab treatment, without statistical significance. Notably, none of the patients that died in the control group were hospit..
Feb 12
Lilly (Preprint) A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
36% improved viral clearance [p=0.07]. RCT with 127 bamlanivimab, etesevimab, and bebtelovimab patients, 125 bebtelovimab patients, and 128 control patients, showing no significant differences in hospitalization and mortality. Viral clearance was improved although not statisti..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit